Basic Information

Strain Name
C57BL/6-Lrrc32tm1(LRRC32)/Bcgen
Stock Number
110102
Common Name
B-hGARP mice
Background
C57BL/6
NCBI Gene ID
Related Genes
LRRC32 (Leucine-Rich Repeat-Containing Protein 32), GARP (Glycoprotein-A repetitions predominant)

Targeting Strategy

Gene targeting strategy for B-hGARP mice. The exon 1~2 of mouse Lrrc32 gene that encode the extracellular domain were replaced by human LRRC32 exon 1~2 in B-hGARP mice.

mRNA expression analysis

Strain specific analysis of GARP gene expression in WT and B-hGARP mice by RT-PCR. Mouse Garp mRNA was detectable in splenocytes of wild-type (+/+) mice. Human GARP mRNA was detectable only in H/H, but not in +/+ mice.

Protein expression analysis in spleen

Strain specific GARP expression analysis in wild-type C57BL/6 mice and homozygous B-hGARP mice by flow cytometry. Splenocytes were collected from wild-type and homozygous B-hGARP (H/H) mice, and analyzed by flow cytometry with species-specific GARP antibody. Mouse GARP was detectable in wild-type mice. Human GARP was exclusively detectable in homozygous B-hGARP but not wild-type mice.

Protein expression analysis in activated T cells

Strain specific GARP expression analysis in wild-type C57BL/6 mice and homozygous B-hGARP mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice and homozygous B-hGARP mice, stimulated with anti-CD3ε (2 μg/mL), anti-CD28(2 μg/mL) in vitro (stimulation for 24 hours). Mouse GARP was exclusively detectable in wild-type mice. Human GARP was exclusively detectable in homozygous B-hGARP mice but not in wild-type mice.

Protein expression analysis in platelet

Strain specific GARP expression analysis in homozygous B-hGARP mice by flow cytometry. Blood were isolated  from wild-type C57BL/6 mice and homozygous B-hGARP mice, and platelet were gated for mCD41 population and used for further analysis as indicated here. Human GARP was only detectable in homozygous homozygous B-hGARP mice.

Analysis of spleen leukocyte subpopulations in B-hGARP mice

Analysis of splenic leukocyte subpopulations by FACS

Splenocytes were isolated from female C57BL/6 and B-hGARP mice (n=3, 6 weeks-old) and analyzed by flow cytometry to assess leukocyte subpopulations. (A) Representative FACS plots gated on single live CD45+ cells for further analysis. (B) Results of FACS analysis. Percentages of T, B, NK cells, monocyte/macrophages, and DC were similar in homozygous B-hGARP mice and C57BL/6 mice, demonstrating that introduction of hGARP in place of its mouse counterpart does not change the overall development, differentiation, or distribution of these cell types in spleen. Values are expressed as mean ± SEM.

Analysis of splenic T cell subpopulations by FACS

Splenocytes were isolated from female C57BL/6 and B-hGARP mice (n=3, 6 weeks-old) and analyzed by flow cytometry for T cell subsets. (A) Representative FACS plots gated on CD3+ T cells and further analyzed. (B) Results of FACS analysis. Percentages of CD8+, CD4+, and Treg cells were similar in homozygous B-hGARP and C57BL/6 mice, demonstrating that introduction of hGARP in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in spleen. Values are expressed as mean ± SEM.

Analysis of blood leukocyte subpopulations in B-hGARP mice

Analysis of blood leukocyte subpopulations by FACS

Blood were isolated from female C57BL/6 and B-hGARP mice (n=3, 6 weeks-old) and analyzed by flow cytometry to assess leukocyte subpopulations. (A) Representative FACS plots gated on single live CD45+ cells for further analysis. (B) Results of FACS analysis. Percentages of T, B, NK cells, monocyte/macrophages, and DC were similar in homozygous B-hGARP mice and C57BL/6 mice, demonstrating that introduction of hGARP in place of its mouse counterpart does not change the overall development, differentiation, or distribution of these cell types in blood. Values are expressed as mean ± SEM.

Analysis of blood T cell subpopulations by FACS

Blood were isolated from female C57BL/6 and B-hGARP mice (n=3, 6 weeks-old) and analyzed by flow cytometry for T cell subsets. (A) Representative FACS plots gated on CD3+ T cells and further analyzed. (B) Results of FACS analysis. Percentages of CD8+, CD4+, and Treg cells were similar in homozygous B-hGARP and C57BL/6 mice, demonstrating that introduction of hGARP in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in blood. Values are expressed as mean ± SEM.

Blood routine tests of B-hGARP mice

Blood routine tests of B-hGARP mice. Blood from female C57BL/6 and B-hGARP mice (n=6, 6 week-old, female) were collected and analyzed for CBC. Any measurement of B-hGARP mice in the panel were similar to C57BL/6, indicating that humanized mouse does not change blood cell composition and morphology. Values are expressed as mean ± SEM.

Blood chemistry of B-hGARP mice

Blood chemistry tests of B-hGARP mice. Serum from C57BL/6 and B-hGARP mice (n=6, 6 week-old, female) were collected and analyzed for levels of ALT, AST and other indicators in the panel. There was no differences on either measurement between C57BL/6 and humanized mouse, indicating that humanized mouse does not change ALT and AST levels or health of liver. Values are expressed as mean ± SEM.

Combination therapy of anti-mouse PD-1 antibody and anti-human GARP/latent-TGFβ1 antibody

Antitumor activity of anti-mouse PD-1 antibody combined with anti-human GARP/latent-TGFβ1 antibody in B-hGARP mice. (A) Anti-mouse PD-1 antibody combined with anti-human GARP/latent-TGFβ1 antibody (in house) inhibited MC38 tumor growth in B-hGARP mice. Murine colon cancer MC38 cells (5E5) were subcutaneously implanted into homozygous B-hGARP mice (female, 7-week-old, n=6). Mice were grouped when tumor volume reached approximately 50~70 mm3, at which time they were treated with anti-mouse PD-1 antibody and anti-human GARP/latent-TGFβ1 antibody with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, combination of anti-mPD-1 antibody and anti-human GARP/latent-TGFβ1 antibody were efficacious in controlling tumor growth in B-hGARP, demonstrating that the B-hGARP mice provide a powerful preclinical model for in vivo evaluation of anti-human GARP antibodies. Values are expressed as mean ± SEM.

Poster

AACR 2022: Generation and Validation of Humanized GARP Mice for Testing Novel Anti-Human GARP Antibodies

Back to top